Brief: Editas Medicine And Maxcyte Announce Clinical And Commercial License Deal For Engineered Cell Medicines
07/10/2019 13:28
Oct 7 (Reuters) - Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE AND MAXCYTE ANNOUNCE CLINICAL AND
COMMERCIAL
LICENSE AGREEMENT FOR ENGINEERED CELL MEDICINES
* EDITAS MEDICINE INC - UNDER TERMS OF AGREEMENT, CO OBTAINS
NON-EXCLUSIVE CLINICAL & COMMERCIAL USE RIGHTS TO MAXCYTE'S CELL
ENGINEERING PLATFORM
* EDITAS MEDICINE - UNDER TERMS , MAXCYTE WILL RECEIVE
DEVELOPMENT & APPROVAL MILESTONES & SALES-BASED PAYMENTS IN
ADDITION TO OTHER LICENSING FEES
Source text for Eikon: ID:nGNX9RjtvG
Further company coverage: EDIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics